ArticleBJS open2026
Survival impact of involvement of lymph node stations 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary cancers (PANODE): prospective multicentre study.
Article in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundCurrent guidelines do not recommend routine sampling of lymph node stations (LNS) 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic ductal adenocarcinoma (PDAC) and other periampullary cancers because prospective multicentre studies are lacking. This study evaluated the association between the involvement of these LNS and overall survival (OS).
methodsThis prospective multicentre study included patients undergoing pancreatoduodenectomy for PDAC, distal cholangiocarcinoma, ampullary cancer, or duodenal cancer between October 2015 and April 2020. Associations between involvement of LNS 16b1, 9, and 8a and OS were analysed using multivariable Cox regression analyses.
resultsAmong 1218 included patients, 673 had PDAC, 228 had distal cholangiocarcinoma, 212 had ampullary cancer, and 105 had duodenal cancer. LNS 16b1 involvement was associated with worse OS in PDAC (10 versus 24 months; adjusted hazard ratio (aHR) 2.33; 95% confidence interval (c.i.) 1.62 to 3.35), distal cholangiocarcinoma (7 versus 28 months; aHR 6.95; 95% c.i. 2.88 to 16.77), ampullary cancer (9 versus 62 months; aHR 4.35; 95% c.i. 1.73 to 10.94), and duodenal cancer (13 months versus endpoint not reached; aHR 3.95; 95% c.i. 1.15 to 13.47). LNS 8a involvement was associated with worse OS in PDAC (13 versus 22 months; aHR 1.38; 95% c.i. 1.03 to 1.86), distal cholangiocarcinoma (16 versus 26 months; aHR 1.68; 95% c.i. 1.00 to 2.81), and ampullary cancer (16 versus 62 months; aHR 2.89; 95% c.i. 1.51 to 5.53). LNS 9 involvement was associated with worse OS only in ampullary cancer (4 versus 35 months; aHR 8.19; 95% c.i. 2.34 to 28.57).
conclusionLNS 16b1 involvement was associated with poor OS in PDAC and periampullary cancer. Future studies should assess routine preoperative and intraoperative sampling of LNS 16b1 and the impact of neoadjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.